Erratum to: Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study (Diabetes Therapy, (2018), 9, 1, (363-371), 10.1007/s13300-017-0338-4)

Risultato della ricerca: Comment/debatepeer review

1 Citazioni (Scopus)

Abstract

In the original publication, the funding statement was incorrectly published and the Editorial Assistant information was missed in the published version. The correct funding statement and the Editorial Assistant statement should read as below. Funding. The study and article processing charges were funded by Novo Nordisk S.p.A. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and the accuracy of the data analysis. Editorial Assistance. Editorial assistance was provided by Paolo de Gennaro of Airon Communication. Support for this assistance was funded by Novo Nordisk S.p.A.
Lingua originaleEnglish
pagine (da-a)1413-1413
Numero di pagine1
RivistaDiabetes Therapy
Volume9
Stato di pubblicazionePublished - 2018

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Fingerprint Entra nei temi di ricerca di 'Erratum to: Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study (Diabetes Therapy, (2018), 9, 1, (363-371), 10.1007/s13300-017-0338-4)'. Insieme formano una fingerprint unica.

Cita questo